Cholinergic neuropathology in a mouse model of Alzheimer's disease
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Transgenic mice overexpressing mutant human amyloid precursor protein (PDAPP mice) develop several Alzheimer's disease (AD)–like lesions including an age‐related accumulation of amyloid‐β (Aβ)–containing neuritic plaques. Although aged, heterozygous PDAPP mice also exhibit synaptic and glial cell changes characteristic of AD pathology, no evidence of widespread neuronal loss has been observed. The present study sought to determine whether homozygous PDAPP mice, which express very high levels of Aβ peptide, exhibit AD‐like cholinergic degenerative changes, and whether the changes parallel the deposition of Aβ plaques. Mice were examined at 2 and 4 months and at 1 and 2 years of age. There was an age‐related increase in the density of Aβ plaques in the cortex and hippocampus of the PDAPP animals; at 4 months of age there were very few plaques, and at 2 years there was a very high density of plaques. There was an age‐related reduction in the density of cholinergic nerve terminals in the cerebral cortex; at 2 months there was a normal density of nerve terminals, but as early as age 4 months there was an approximately 50% reduction. However, at age 2 years there was no difference in the number or size of basal forebrain cholinergic somata compared with 2‐month‐old PDAPP mice. These data indicated that the homozygous PDAPP mouse exhibits cholinergic nerve terminal degenerative pathology and that the cortical neurodegenerative changes occur before the deposition of Aβ‐containing neuritic plaques. J. Comp. Neurol. 462:371–381, 2003. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627 · cited 2×
“The reductions are 30% to 95% in AD postmortem brain (Whitehouse et al., 1982; Arendt et al., 1983; Wilcock et al., 1983; Mann et al., 1984; Rinne et al., 1987; Vogels et al., 1990).”
BackgroundSELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · cited 1×
“The first subcortical nucleus found to degenerate in AD was the nucleus basalis of Meynert (Bowen et al., 1976; Davies and Maloney, 1976; Perry et al., 1977; Whitehouse et al., 1982), which contains cholinergic neurons (Mesulam and Geula, 1988).”
BackgroundImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Self-citationAlzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 4×
“The mature plaques contained large amounts of A immunoreactivity and were previously shown to stain intensely for thioflavin-S and Congo red (Games et al., 1995).”
BackgroundSelf-citationMucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“For example, behavioral impairments (Holcomb et al., 1998; Moechars et al., 1999), synaptic transmission deficits (Hsia et al., 1999), and loss of cortical nerve terminal markers in the PDAPP mouse (Mucke et al., 2000) precede the formation of neuritic plaques in APP mouse models of AD.”
BackgroundAβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431 · cited 1×
“Immunization with A has been found to markedly reduce neuritic plaque formation and plaque progression in the PDAPP mouse (Schenk et al., 1999) and to reduce learning deficits in AD mouse models (Janus et al., 2000; Morgan et al., 2000).”
BackgroundHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
A mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease
Murrell, J., Farlow, M., Ghetti, B., & Benson, M. D. (1991) · Science · doi:10.1126/science.1925564 · Cited by 1,127
Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models
Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G.-Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A., & Mucke, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3228 · Cited by 1,123 · cited 1×
“For example, behavioral impairments (Holcomb et al., 1998; Moechars et al., 1999), synaptic transmission deficits (Hsia et al., 1999), and loss of cortical nerve terminal markers in the PDAPP mouse (Mucke et al., 2000) precede the formation of neuritic plaques in APP mouse models of AD.”
BackgroundAmyloid β-Protein Fibrillogenesis
Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., & Teplow, D. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25945 · Cited by 1,046 · cited 1×
“The protofibrils have been shown to be neurotoxic (Hartley et al., 1999; Walsh et al., 1999).”
BackgroundImpaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., Younkin, L., Good, M. A., Bliss, T. V. P., Hyman, B. T., et al. (1999) · Nature Neuroscience · doi:10.1038/6374 · Cited by 946 · cited 1×
“…synaptic transmission is important for learning and memory (Coyle et al., 1983; Fibiger, 1991), reductions in cholinergic nerve terminals may play a part in the learning deficits observed in APP transgenic mice (Chapman et al., 1999; Morgan et al., 2000) and in the PDAPP mouse (Chen et al., 2000).”
BackgroundNew stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940 · cited 1×
“Cholinergic varicosity counts were performed by using the optical dissector probe (West, 1993) in ChATimmunostained coronal sections (section thickness after immunostaining 16 m).”
MethodImmunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858
Rye, D. B., Wainer, B. H., Mesulam, M.-M., Mufson, E. J., & Saper, C. B. (1984) · Neuroscience · doi:10.1016/0306-4522(84)90083-6 · Cited by 743
A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., Justice, A., McConlogue, L., Games, D., Freedman, S. B., et al. (2000) · Nature · doi:10.1038/35050103 · Cited by 740
Self-citationDeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686 · cited 1×
“…postmortem brain, where there are marked decreases in the density of cholinergic nerve terminals and ChAT enzyme activity (Geula and Mesulam, 1996; DeKosky et al., 2002), and the cholinergic deficits are positively correlated with the level of cognitive impairment in AD patients (Perry et al.,…”
BackgroundMoechars, D., Dewachter, I., Lorent, K., Reversé, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C. V. D., Checler, F., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6483 · Cited by 668
Irizarry, M. C., Soriano, F., McNamara, M., Page, K. J., Schenk, D., Games, D., & Hyman, B. T. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-18-07053.1997 · Cited by 497 · cited 1×
“Heterozygous 18-monthold PDAPP mice have been examined for cortical cell loss, but none has been found even in regions that contain a high density of plaques (Irizarry et al., 1997).”
BackgroundSelf-citationSystematic Regional Variations in the Loss of Cortical Cholinergic Fibers in Alzheimer's Disease
Geula, C., & Mesulam, M.-M. (1996) · Cerebral Cortex · doi:10.1093/cercor/6.2.165 · Cited by 202
Wong, T. P., Debeir, T., Duff, K., & Cuello, A. C. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02706.1999 · Cited by 196 · cited 3×
“Several studies have found evidence of cholinergic nerve terminal abnormalities in AD mouse models (Wong et al., 1999; Bronfman et al., 2000; Sturchler-Pierrat and Staufenbiel, 2000; Hernandez et al., 2001; Jaffar et al., 2001; Boncristiano et al., 2002), but they have not found evidence of…”
BackgroundCholinergic Changes in the APP23 Transgenic Mouse Model of Cerebral Amyloidosis
Boncristiano, S., Calhoun, M. E., Kelly, P. H., Pfeifer, M., Bondolfi, L., Stalder, M., Phinney, A. L., Abramowski, D., Sturchler-Pierrat, C., Enz, A., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03234.2002 · Cited by 160 · cited 6×
“…evidence of cholinergic nerve terminal abnormalities in AD mouse models (Wong et al., 1999; Bronfman et al., 2000; Sturchler-Pierrat and Staufenbiel, 2000; Hernandez et al., 2001; Jaffar et al., 2001; Boncristiano et al., 2002), but they have not found evidence of cholinergic cell degeneration.”
BackgroundResultInfluentialHernandez, D., Sugaya, K., Qu, T., McGowan, E., Duff, K., & McKinney, M. (2001) · Neuroreport · doi:10.1097/00001756-200105250-00018 · Cited by 73
Cited by
Alzheimer disease models and human neuropathology: similarities and differences
Duyckaerts, C., Potier, M.-C., & Delatour, B. (2008) · Acta Neuropathologica · doi:10.1007/s00401-007-0312-8 · Cited by 375
The history of the cholinergic hypothesis
Contestabile, A. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.12.044 · Cited by 374
Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease
Donovan, M. H., Yazdani, U., Norris, R. D., Games, D., German, D. C., & Eisch, A. J. (2006) · The Journal of Comparative Neurology · doi:10.1002/cne.20840 · Cited by 351
Self-citationDivide and Die: Cell Cycle Events as Triggers of Nerve Cell Death
Herrup, K., Neve, R., Ackerman, S. L., & Copani, A. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3347-04.2004 · Cited by 287
Knowles, J. K., Rajadas, J., Nguyen, T.-V. V., Yang, T., LeMieux, M. C., Vander Griend, L., Ishikawa, C., Massa, S. M., Wyss-Coray, T., & Longo, F. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0620-09.2009 · Cited by 184
“In contrast, neuritic degeneration, including that associated with BFCNs, has been documented in mouse models of AD (Stokin et al., 2005) and in AD patients (Wong et al., 1999; German et al., 2003; Stokin et al., 2005).”
Background
Metadata
- Authors
- German, D. C., Yazdani, U., Speciale, S. G., Pasbakhsh, P., Games, D., & Liang, C.
- Venue
- Journal of Comparative Neurology
- Publisher
- Wiley
- Published
- 2003-06-10
- Volume
- 462
- Issue
- 4
- Pages
- 371-381
- ISSN
- 0021-9967 (ISSN-L)
- 1096-9861
- OpenAlex
- W2025103036
- Cited by
- 101
- References
- 23
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.